MovDisordV3, PascalFrancis, Corpus, bibRecord, 002617

Olanzapine treatment for dopaminergic-induced hallucinations

Identifieur interne : 002617 ( PascalFrancis/Corpus ); précédent : 002616; suivant : 002618

Olanzapine treatment for dopaminergic-induced hallucinations

Auteurs : William G. Ondo ; Joel K. Levy ; Kevin Dat Vuong ; Christine Hunter ; Joseph Jankovic

Source :

Movement disorders [ 0885-3185 ] ; 2002.

RBID : Pascal:02-0584504

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Hallucination, Olanzapine, Neuroleptique, Dose faible, Agoniste, Récepteur dopaminergique, Chimiothérapie, Traitement, Homme, Cognition, Humeur, Antipsychotique, Atypique, Thiéno benzodiazépine dérivé.

English descriptors

KwdEn :
- Agonist, Antipsychotic, Atypical, Chemotherapy, Cognition, Dopamine receptor, Hallucination, Human, Low dose, Mood, Neuroleptic, Olanzapine, Parkinson disease, Treatment.

Abstract

Atypical antipsychotic medications with lower affinities for D2 receptors are considered useful alternatives to treat drug-induced hallucinations in Parkinson's disease (PD). We conducted a double-blind, placebo-controlled, unforced titration, parallel design study (2:1 drug to placebo randomization ratio) using olanzapine (2.5-10 mg/day to effect) in 30 PD patients with drug-induced hallucinations. We performed an extensive battery of neuropsychological tests, the Unified Parkinson's Disease Rating Scale (UPDRS), assessments of on and off time at baseline and at 9 weeks after starting the medication. Sixteen patients on olanzapine (mean dose, 4.6 mg/night) and I on placebo completed the study. Compared with placebo, performance on the UPDRS item 2 (thought disorder), and a structured interview for hallucinations, both tended to improve on drug but neither reached statistical significance. A neuropsychological test battery did not show any significant differences. Total on UPDRS motor scores (P < 0.05) and timed tapping (P < 0.01) worsened while on drug compared to placebo. Bradykinesia (P < 0.01) and gait (P < 0.001) items on the UPDRS largely accounted for this deterioration. After completion of the study, 8 of 16 patients randomly assigned to drug continued olanzapine at a mean dose of 2.4 mg/day. However, at the last recorded visit only 5 of 24 (20.8%) of all patients exposed to drug (including those originally randomly assigned to placebo) remained on olanzapine. In patients with PD, low-dose olanzapine did not significantly improve hallucinations but did worsen motor function.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 17`
A06				`@2 5`
A08	`01`	`1`	`ENG`	`@1 Olanzapine treatment for dopaminergic-induced hallucinations`
A11	`01`	`1`		`@1 ONDO (William G.)`
A11	`02`	`1`		`@1 LEVY (Joel K.)`
A11	`03`	`1`		`@1 DAT VUONG (Kevin)`
A11	`04`	`1`		`@1 HUNTER (Christine)`
A11	`05`	`1`		`@1 JANKOVIC (Joseph)`
A14	`01`			`@1 Department of Neurology, Baylor College of Medicine @2 Houston, Texas @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut.`
A20				`@1 1031-1035`
A21				`@1 2002`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000105152380210`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 21 ref.`
A47	`01`	`1`		`@0 02-0584504`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Atypical antipsychotic medications with lower affinities for D2 receptors are considered useful alternatives to treat drug-induced hallucinations in Parkinson's disease (PD). We conducted a double-blind, placebo-controlled, unforced titration, parallel design study (2:1 drug to placebo randomization ratio) using olanzapine (2.5-10 mg/day to effect) in 30 PD patients with drug-induced hallucinations. We performed an extensive battery of neuropsychological tests, the Unified Parkinson's Disease Rating Scale (UPDRS), assessments of on and off time at baseline and at 9 weeks after starting the medication. Sixteen patients on olanzapine (mean dose, 4.6 mg/night) and I on placebo completed the study. Compared with placebo, performance on the UPDRS item 2 (thought disorder), and a structured interview for hallucinations, both tended to improve on drug but neither reached statistical significance. A neuropsychological test battery did not show any significant differences. Total on UPDRS motor scores (P < 0.05) and timed tapping (P < 0.01) worsened while on drug compared to placebo. Bradykinesia (P < 0.01) and gait (P < 0.001) items on the UPDRS largely accounted for this deterioration. After completion of the study, 8 of 16 patients randomly assigned to drug continued olanzapine at a mean dose of 2.4 mg/day. However, at the last recorded visit only 5 of 24 (20.8%) of all patients exposed to drug (including those originally randomly assigned to placebo) remained on olanzapine. In patients with PD, low-dose olanzapine did not significantly improve hallucinations but did worsen motor function.
C02	`01`	`X`		`@0 002B02B03`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Hallucination @5 04`
C03	`02`	`X`	`ENG`	`@0 Hallucination @5 04`
C03	`02`	`X`	`SPA`	`@0 Alucinación @5 04`
C03	`03`	`X`	`FRE`	`@0 Olanzapine @2 NK @2 FR @5 07`
C03	`03`	`X`	`ENG`	`@0 Olanzapine @2 NK @2 FR @5 07`
C03	`03`	`X`	`SPA`	`@0 Olanzapina @2 NK @2 FR @5 07`
C03	`04`	`X`	`FRE`	`@0 Neuroleptique @5 08`
C03	`04`	`X`	`ENG`	`@0 Neuroleptic @5 08`
C03	`04`	`X`	`SPA`	`@0 Neuroléptico @5 08`
C03	`05`	`X`	`FRE`	`@0 Dose faible @5 10`
C03	`05`	`X`	`ENG`	`@0 Low dose @5 10`
C03	`05`	`X`	`SPA`	`@0 Dosis débil @5 10`
C03	`06`	`X`	`FRE`	`@0 Agoniste @5 13`
C03	`06`	`X`	`ENG`	`@0 Agonist @5 13`
C03	`06`	`X`	`SPA`	`@0 Agonista @5 13`
C03	`07`	`X`	`FRE`	`@0 Récepteur dopaminergique @5 14`
C03	`07`	`X`	`ENG`	`@0 Dopamine receptor @5 14`
C03	`07`	`X`	`SPA`	`@0 Receptor dopaminérgico @5 14`
C03	`08`	`X`	`FRE`	`@0 Chimiothérapie @5 16`
C03	`08`	`X`	`ENG`	`@0 Chemotherapy @5 16`
C03	`08`	`X`	`SPA`	`@0 Quimioterapia @5 16`
C03	`09`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`09`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`09`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`10`	`X`	`FRE`	`@0 Homme @5 20`
C03	`10`	`X`	`ENG`	`@0 Human @5 20`
C03	`10`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`11`	`X`	`FRE`	`@0 Cognition @5 23`
C03	`11`	`X`	`ENG`	`@0 Cognition @5 23`
C03	`11`	`X`	`SPA`	`@0 Cognición @5 23`
C03	`12`	`X`	`FRE`	`@0 Humeur @5 24`
C03	`12`	`X`	`ENG`	`@0 Mood @5 24`
C03	`12`	`X`	`SPA`	`@0 Humor @5 24`
C03	`13`	`X`	`FRE`	`@0 Antipsychotique @5 35`
C03	`13`	`X`	`ENG`	`@0 Antipsychotic @5 35`
C03	`13`	`X`	`SPA`	`@0 Antipsicótico @5 35`
C03	`14`	`X`	`FRE`	`@0 Atypique @5 36`
C03	`14`	`X`	`ENG`	`@0 Atypical @5 36`
C03	`14`	`X`	`SPA`	`@0 Atípico @5 36`
C03	`15`	`X`	`FRE`	`@0 Thiéno benzodiazépine dérivé @4 INC @5 92`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Posologie @5 61`
C07	`06`	`X`	`ENG`	`@0 Posology @5 61`
C07	`06`	`X`	`SPA`	`@0 Posología @5 61`
N21				`@1 343`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 02-0584504 INIST
ET :	Olanzapine treatment for dopaminergic-induced hallucinations
AU :	ONDO (William G.); LEVY (Joel K.); DAT VUONG (Kevin); HUNTER (Christine); JANKOVIC (Joseph)
AF :	Department of Neurology, Baylor College of Medicine/Houston, Texas/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.)
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 5; Pp. 1031-1035; Bibl. 21 ref.
LA :	Anglais
EA :	Atypical antipsychotic medications with lower affinities for D2 receptors are considered useful alternatives to treat drug-induced hallucinations in Parkinson's disease (PD). We conducted a double-blind, placebo-controlled, unforced titration, parallel design study (2:1 drug to placebo randomization ratio) using olanzapine (2.5-10 mg/day to effect) in 30 PD patients with drug-induced hallucinations. We performed an extensive battery of neuropsychological tests, the Unified Parkinson's Disease Rating Scale (UPDRS), assessments of on and off time at baseline and at 9 weeks after starting the medication. Sixteen patients on olanzapine (mean dose, 4.6 mg/night) and I on placebo completed the study. Compared with placebo, performance on the UPDRS item 2 (thought disorder), and a structured interview for hallucinations, both tended to improve on drug but neither reached statistical significance. A neuropsychological test battery did not show any significant differences. Total on UPDRS motor scores (P < 0.05) and timed tapping (P < 0.01) worsened while on drug compared to placebo. Bradykinesia (P < 0.01) and gait (P < 0.001) items on the UPDRS largely accounted for this deterioration. After completion of the study, 8 of 16 patients randomly assigned to drug continued olanzapine at a mean dose of 2.4 mg/day. However, at the last recorded visit only 5 of 24 (20.8%) of all patients exposed to drug (including those originally randomly assigned to placebo) remained on olanzapine. In patients with PD, low-dose olanzapine did not significantly improve hallucinations but did worsen motor function.
CC :	002B02B03; 002B17G
FD :	Parkinson maladie; Hallucination; Olanzapine; Neuroleptique; Dose faible; Agoniste; Récepteur dopaminergique; Chimiothérapie; Traitement; Homme; Cognition; Humeur; Antipsychotique; Atypique; Thiéno benzodiazépine dérivé
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Posologie
ED :	Parkinson disease; Hallucination; Olanzapine; Neuroleptic; Low dose; Agonist; Dopamine receptor; Chemotherapy; Treatment; Human; Cognition; Mood; Antipsychotic; Atypical
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Posology
SD :	Parkinson enfermedad; Alucinación; Olanzapina; Neuroléptico; Dosis débil; Agonista; Receptor dopaminérgico; Quimioterapia; Tratamiento; Hombre; Cognición; Humor; Antipsicótico; Atípico
LO :	INIST-20953.354000105152380210
ID :	02-0584504

Links to Exploration step

Pascal:02-0584504

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Olanzapine treatment for dopaminergic-induced hallucinations</title>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Levy, Joel K" sort="Levy, Joel K" uniqKey="Levy J" first="Joel K." last="Levy">Joel K. Levy</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dat Vuong, Kevin" sort="Dat Vuong, Kevin" uniqKey="Dat Vuong K" first="Kevin" last="Dat Vuong">Kevin Dat Vuong</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hunter, Christine" sort="Hunter, Christine" uniqKey="Hunter C" first="Christine" last="Hunter">Christine Hunter</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0584504</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0584504 INIST</idno>
<idno type="RBID">Pascal:02-0584504</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002617</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Olanzapine treatment for dopaminergic-induced hallucinations</title>
<author><name sortKey="Ondo, William G" sort="Ondo, William G" uniqKey="Ondo W" first="William G." last="Ondo">William G. Ondo</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Levy, Joel K" sort="Levy, Joel K" uniqKey="Levy J" first="Joel K." last="Levy">Joel K. Levy</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dat Vuong, Kevin" sort="Dat Vuong, Kevin" uniqKey="Dat Vuong K" first="Kevin" last="Dat Vuong">Kevin Dat Vuong</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hunter, Christine" sort="Hunter, Christine" uniqKey="Hunter C" first="Christine" last="Hunter">Christine Hunter</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Antipsychotic</term>
<term>Atypical</term>
<term>Chemotherapy</term>
<term>Cognition</term>
<term>Dopamine receptor</term>
<term>Hallucination</term>
<term>Human</term>
<term>Low dose</term>
<term>Mood</term>
<term>Neuroleptic</term>
<term>Olanzapine</term>
<term>Parkinson disease</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Hallucination</term>
<term>Olanzapine</term>
<term>Neuroleptique</term>
<term>Dose faible</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
<term>Cognition</term>
<term>Humeur</term>
<term>Antipsychotique</term>
<term>Atypique</term>
<term>Thiéno benzodiazépine dérivé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Atypical antipsychotic medications with lower affinities for D2 receptors are considered useful alternatives to treat drug-induced hallucinations in Parkinson's disease (PD). We conducted a double-blind, placebo-controlled, unforced titration, parallel design study (2:1 drug to placebo randomization ratio) using olanzapine (2.5-10 mg/day to effect) in 30 PD patients with drug-induced hallucinations. We performed an extensive battery of neuropsychological tests, the Unified Parkinson's Disease Rating Scale (UPDRS), assessments of on and off time at baseline and at 9 weeks after starting the medication. Sixteen patients on olanzapine (mean dose, 4.6 mg/night) and I on placebo completed the study. Compared with placebo, performance on the UPDRS item 2 (thought disorder), and a structured interview for hallucinations, both tended to improve on drug but neither reached statistical significance. A neuropsychological test battery did not show any significant differences. Total on UPDRS motor scores (P < 0.05) and timed tapping (P < 0.01) worsened while on drug compared to placebo. Bradykinesia (P < 0.01) and gait (P < 0.001) items on the UPDRS largely accounted for this deterioration. After completion of the study, 8 of 16 patients randomly assigned to drug continued olanzapine at a mean dose of 2.4 mg/day. However, at the last recorded visit only 5 of 24 (20.8%) of all patients exposed to drug (including those originally randomly assigned to placebo) remained on olanzapine. In patients with PD, low-dose olanzapine did not significantly improve hallucinations but did worsen motor function.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s2>5</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Olanzapine treatment for dopaminergic-induced hallucinations</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>ONDO (William G.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>LEVY (Joel K.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DAT VUONG (Kevin)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HUNTER (Christine)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>JANKOVIC (Joseph)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Baylor College of Medicine</s1>
<s2>Houston, Texas</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
</fA14>
<fA20><s1>1031-1035</s1>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000105152380210</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0584504</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Atypical antipsychotic medications with lower affinities for D2 receptors are considered useful alternatives to treat drug-induced hallucinations in Parkinson's disease (PD). We conducted a double-blind, placebo-controlled, unforced titration, parallel design study (2:1 drug to placebo randomization ratio) using olanzapine (2.5-10 mg/day to effect) in 30 PD patients with drug-induced hallucinations. We performed an extensive battery of neuropsychological tests, the Unified Parkinson's Disease Rating Scale (UPDRS), assessments of on and off time at baseline and at 9 weeks after starting the medication. Sixteen patients on olanzapine (mean dose, 4.6 mg/night) and I on placebo completed the study. Compared with placebo, performance on the UPDRS item 2 (thought disorder), and a structured interview for hallucinations, both tended to improve on drug but neither reached statistical significance. A neuropsychological test battery did not show any significant differences. Total on UPDRS motor scores (P < 0.05) and timed tapping (P < 0.01) worsened while on drug compared to placebo. Bradykinesia (P < 0.01) and gait (P < 0.001) items on the UPDRS largely accounted for this deterioration. After completion of the study, 8 of 16 patients randomly assigned to drug continued olanzapine at a mean dose of 2.4 mg/day. However, at the last recorded visit only 5 of 24 (20.8%) of all patients exposed to drug (including those originally randomly assigned to placebo) remained on olanzapine. In patients with PD, low-dose olanzapine did not significantly improve hallucinations but did worsen motor function.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02B03</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Hallucination</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Hallucination</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Alucinación</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Olanzapine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Olanzapine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Olanzapina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Neuroleptique</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Neuroleptic</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Neuroléptico</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Dose faible</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Low dose</s0>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Dosis débil</s0>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Agonist</s0>
<s5>13</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Agonista</s0>
<s5>13</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>14</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>14</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Cognition</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Cognition</s0>
<s5>23</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Cognición</s0>
<s5>23</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Humeur</s0>
<s5>24</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Mood</s0>
<s5>24</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Humor</s0>
<s5>24</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Antipsychotique</s0>
<s5>35</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Antipsychotic</s0>
<s5>35</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Antipsicótico</s0>
<s5>35</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Atypique</s0>
<s5>36</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Atypical</s0>
<s5>36</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Atípico</s0>
<s5>36</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Thiéno benzodiazépine dérivé</s0>
<s4>INC</s4>
<s5>92</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Posologie</s0>
<s5>61</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Posology</s0>
<s5>61</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Posología</s0>
<s5>61</s5>
</fC07>
<fN21><s1>343</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 02-0584504 INIST</NO>
<ET>Olanzapine treatment for dopaminergic-induced hallucinations</ET>
<AU>ONDO (William G.); LEVY (Joel K.); DAT VUONG (Kevin); HUNTER (Christine); JANKOVIC (Joseph)</AU>
<AF>Department of Neurology, Baylor College of Medicine/Houston, Texas/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. 5; Pp. 1031-1035; Bibl. 21 ref.</SO>
<LA>Anglais</LA>
<EA>Atypical antipsychotic medications with lower affinities for D2 receptors are considered useful alternatives to treat drug-induced hallucinations in Parkinson's disease (PD). We conducted a double-blind, placebo-controlled, unforced titration, parallel design study (2:1 drug to placebo randomization ratio) using olanzapine (2.5-10 mg/day to effect) in 30 PD patients with drug-induced hallucinations. We performed an extensive battery of neuropsychological tests, the Unified Parkinson's Disease Rating Scale (UPDRS), assessments of on and off time at baseline and at 9 weeks after starting the medication. Sixteen patients on olanzapine (mean dose, 4.6 mg/night) and I on placebo completed the study. Compared with placebo, performance on the UPDRS item 2 (thought disorder), and a structured interview for hallucinations, both tended to improve on drug but neither reached statistical significance. A neuropsychological test battery did not show any significant differences. Total on UPDRS motor scores (P < 0.05) and timed tapping (P < 0.01) worsened while on drug compared to placebo. Bradykinesia (P < 0.01) and gait (P < 0.001) items on the UPDRS largely accounted for this deterioration. After completion of the study, 8 of 16 patients randomly assigned to drug continued olanzapine at a mean dose of 2.4 mg/day. However, at the last recorded visit only 5 of 24 (20.8%) of all patients exposed to drug (including those originally randomly assigned to placebo) remained on olanzapine. In patients with PD, low-dose olanzapine did not significantly improve hallucinations but did worsen motor function.</EA>
<CC>002B02B03; 002B17G</CC>
<FD>Parkinson maladie; Hallucination; Olanzapine; Neuroleptique; Dose faible; Agoniste; Récepteur dopaminergique; Chimiothérapie; Traitement; Homme; Cognition; Humeur; Antipsychotique; Atypique; Thiéno benzodiazépine dérivé</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Posologie</FG>
<ED>Parkinson disease; Hallucination; Olanzapine; Neuroleptic; Low dose; Agonist; Dopamine receptor; Chemotherapy; Treatment; Human; Cognition; Mood; Antipsychotic; Atypical</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Posology</EG>
<SD>Parkinson enfermedad; Alucinación; Olanzapina; Neuroléptico; Dosis débil; Agonista; Receptor dopaminérgico; Quimioterapia; Tratamiento; Hombre; Cognición; Humor; Antipsicótico; Atípico</SD>
<LO>INIST-20953.354000105152380210</LO>
<ID>02-0584504</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002617 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002617 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:02-0584504
   |texte=   Olanzapine treatment for dopaminergic-induced hallucinations
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Olanzapine treatment for dopaminergic-induced hallucinations

Olanzapine treatment for dopaminergic-induced hallucinations

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri